文献速递白血病

CD44介导的代谢重编程是IDH突变白血病的可靶向依赖

CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia.
PubMed 文献 · Blood · 2025-01-01

研究通过CRISPR碱基编辑构建同基因白血病细胞比较转录组,发现IDH突变白血病共同激活CD44等黏附分子,且IDH突变AML患者CD44表达升高。CD44通过磷酸化葡萄糖-6-磷酸脱氢酶和丙酮酸激酶M2分别激活磷酸戊糖途径、抑制糖酵解,保障NADPH生成以支持R-2HG产生。IDH抑制联合CD44阻断增强清除IDH突变白血病细胞。

要点

  • IDH突变白血病细胞共同特征为CD44等黏附分子激活,患者CD44表达升高。
  • CD44对IDH突变白血病细胞不可或缺,通过代谢重编程保障NADPH生成。
  • IDH抑制联合CD44阻断增强对IDH突变白血病细胞的清除。

核心结论

  • CD44介导的代谢重编程支持R-2HG产生,构成IDH突变恶性肿瘤的可靶向依赖。
  • IDH抑制联合CD44阻断可增强清除IDH突变白血病细胞。

研究设计与样本

  • 研究比较携带CRISPR碱基编辑IDH突变的同基因白血病细胞的转录组改变。
  • 研究分析IDH突变AML患者的CD44表达。
  • 研究未报告样本量。

主要发现

  • IDH突变白血病细胞共同激活包括CD44在内的黏附分子。
  • IDH突变AML患者CD44表达升高。
  • CD44通过磷酸化葡萄糖-6-磷酸脱氢酶激活磷酸戊糖途径。
  • CD44通过磷酸化丙酮酸激酶M2抑制糖酵解。
  • CD44对IDH突变白血病细胞不可或缺,保障NADPH生成以支持R-2HG产生。

关键数值与推荐

  • IDH突变催化NADPH依赖的致癌代谢物R-2HG产生。
  • IDH抑制在部分AML病例中提供临床反应,但多数患者出现耐药。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrent isocitrate dehydrogenase (IDH) mutations catalyze nicotinamide adenine dinucleotide phosphate (NADPH)-dependent production of oncometabolite (R)-2-hydroxyglutarate (R-2HG) for tumorigenesis. IDH inhibition provides clinical response in a subset of acute myeloid leukemia (AML) cases; however, most patients develop resistance, highlighting the need for more effective IDH-targeting therapies. By comparing transcriptomic alterations in isogenic leukemia cells harboring CRISPR base-edited IDH mutations, we identify the activation of adhesion molecules including CD44, a transmembrane glycoprotein, as a shared feature of IDH-mutant leukemia, consistent with elevated CD44 expression in IDH-mutant AML patients. CD44 is indispensable for IDH-mutant leukemia cells through activating pentose phosphate pathway and inhibiting glycolysis by phosphorylating glucose-6-phosphate dehydrogenase and pyruvate kinase muscle isozyme M2, respectively. This metabolic rewiring ensures efficient NADPH generation for mutant IDH-catalyzed R-2HG production. Combining IDH inhibition with CD44 blockade enhances the elimination of IDH-mutant leukemia cells. Hence, we describe an oncogenic feedforward pathway involving CD44-mediated metabolic rewiring for oncometabolite production, representing a potentially targetable dependency of IDH-mutant malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lyu J, Liu Y, Liu N, et al. CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia. Blood. 2025. PMID: 39841003. doi:10.1182/blood.2024027207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。